(VIANEWS) – Shares of Arcturus Therapeutics (NASDAQ: ARCT) dropped by a staggering 20.17% in 10 sessions from $22.91 at 2023-02-02, to $18.29 at 11:43 EST on Thursday, after three consecutive sessions in a row of losses. NASDAQ is dropping 0.66% to $11,991.44, after three sequential sessions in a row of gains.
Arcturus Therapeutics’s last close was $18.53, 41.01% under its 52-week high of $31.41.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $-3.55.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.48%.
Sales Growth
Arcturus Therapeutics’s sales growth is negative 84.3% for the present quarter and 1.7% for the next.
Yearly Top and Bottom Value
Arcturus Therapeutics’s stock is valued at $18.29 at 11:43 EST, way under its 52-week high of $31.41 and way above its 52-week low of $11.70.
Volume
Today’s last reported volume for Arcturus Therapeutics is 39783 which is 91.06% below its average volume of 421601.
More news about Arcturus Therapeutics (ARCT).
